In addition, IL-2 has been reported to promote the amplification of Tregs and mitigates clinical manifestation in patients with refractory Behçet’s disease.[7,8] However, to date, there has been no report of the effect of low-dose IL-2 treatment on Behçet’s disease. This evidence concerns the gene IL2 and Behcet disease.